Seagen
News/ News/ Sales and Marketing
Court won’t raise Seagen damages award in Enhertu patent dispute
Phil Taylor
AstraZeneca, Daiichi Sankyo, Enhertu, patent litigation, Seagen
0 Comment
Market Access/ News/ News/ News/ Oncology
AZ, Daiichi challenge Roche with EU okay for earlier use of Enhertu
Phil Taylor
AstraZeneca, breast cancer, Daiichi Sankyo, Enhertu, EU, her2, Kadcyla, regulatory approval, Roche, Seagen, Tukysa
0 Comment
News/ News/ News/ Oncology/ Sales and Marketing
Merck in “advanced talks” for $40bn Seagen bid; report
News/ News/ News/ News/ Oncology/ R&D/ Sales and Marketing
Is Merck planning a $30bn-plus move for Seagen?
News/ News/ Sales and Marketing
Seagen wins Enhertu patent dispute with Daiichi Sankyo
Phil Taylor
antibody-drug conjugate, AstraZeneca, Daiichi Sankyo, Enhertu, patent litigation, Seagen
0 Comment
Trial win sets up new use for Astellas, Seagen’s Padcev in bladder cancer
Phil Taylor
antibody-drug conjugate, Astellas, bladder cancer, Oncology, Padcev, Seagen
0 Comment
Seagen’s breast cancer drug Tukysa turned down by NICE
Phil Taylor
breast cancer, HEOR, her2, NICE, Oncology, Seagen, Tukysa
0 Comment